Healthcare [ 4/11 ] | Biotechnology [ 50/148 ]
US | AMEX | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 14, 23 | 0.28 Increased by +207.69% | 0.35 Decreased by -20.00% |
| May 11, 23 | -0.40 Decreased by -33.33% | -0.29 Decreased by -37.93% |
| Mar 16, 23 | -0.29 Decreased by -26.09% | -0.28 Decreased by -3.57% |
| Nov 9, 22 | -0.24 Decreased by -9.09% | -0.28 Increased by +14.29% |
| Aug 11, 22 | -0.26 Decreased by -4.00% | -0.23 Decreased by -13.04% |
| May 12, 22 | -0.30 Decreased by -11.11% | -0.21 Decreased by -42.86% |
| Mar 17, 22 | -0.23 Increased by +36.11% | -0.28 Increased by +17.86% |
| Nov 10, 21 | -0.22 Increased by +29.03% | -0.26 Increased by +15.38% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 0.00 Decreased by N/A% | -3.55 M Increased by +61.49% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -17.63 M Decreased by -101.00% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -10.30 M Decreased by -70.35% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -8.61 M Decreased by -58.79% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -9.21 M Decreased by -48.69% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -8.77 M Decreased by -59.65% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -6.05 M Increased by +8.71% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -5.42 M Increased by +6.07% | Decreased by N/A% Decreased by N/A% |
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.